Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Amphstar Pharmaceuticals (AMPH)

Amphastar to license AMP-110 corticotropin from related party Hanxin in US, Canada

Neutral Impact 3 of 5 product/contract Written later

Amphastar entered into an exclusive license agreement with Nanjing Hanxin Pharmaceutical Technology on January 6, 2026, for AMP-110, a fully synthetic corticotropin compound in early-phase human clinical development, covering the United States and Canada. Hanxin is controlled by family members of Amphastar's CEO and Chairman, so the agreement and two related amendments are related party transactions, and the company says the amendments are not expected to be material.

Key points

  • Amphastar made a $2 million upfront payment to Hanxin, with up to $14 million in development milestones and up to $75 million in sales milestones.
  • Royalties payable by Amphastar to Hanxin are capped at $7.5 million per calendar year and $60 million in total accumulated.
  • Dr. Jack Zhang and Dr. Mary Luo and certain family members own a majority of Hanxin; the Audit Committee approved the distribution and manufacturing amendments.
  • The Distribution and Manufacturing Amendments expand territories; their value is not determinable until sales occur in the expanded regions.

The filing

CompanyAmphstar Pharmaceuticals (AMPH)
Form8-K, current report
Filed with the SECJan 12, 2026, 5:15 PM ET
Accession number0001297184-26-000002

Items reported: 1.01 Material Definitive Agreement7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 12, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.